Aripiprazole for late-life schizophrenia by Rado, Jeffrey & Janicak, Philip G
© 2010 Rado and Janicak, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2010:5 253–258
Clinical Interventions in Aging Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
253
REVIEW
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CIA.S9398
Aripiprazole for late-life schizophrenia
Jeffrey Rado 
Philip G Janicak
Psychiatric Clinical Research Center, 
Rush University Medical Center, 
Chicago, IL, USA
Correspondence: Jeffrey Rado 
Psychiatric Clinical Research Center,  
Rush University Medical Center,  
2150 West Harrison Street,  
Chicago, IL 60612, USA 
Tel +1 312 942 9296 
Fax +1 312 942 7284 
Email jeffrey_rado@rush.edu
Abstract: Antipsychotics are frequently used in elderly patients to treat a variety of conditions, 
including schizophrenia. While extensively studied for their impact in younger   populations, 
there is comparatively limited evidence about the effectiveness of these agents in older patients. 
Further complicating this situation are the high co-morbidity rates (both psychiatric and   medical) 
in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for 
adverse effects; and the potential for multiple, clinically relevant drug interactions. With this 
background in mind, we review diagnostic and treatment-related issues specific to elderly 
patients suffering from schizophrenia and other psychotic conditions, focusing on the potential 
role of aripiprazole.
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Introduction
While the use of psychotropics in elderly patients is common, there is less evidence 
from controlled trials to guide clinicians’ decision making. Further, several issues spe-
cific to this age group complicate prescribing for the elderly. These include age-related 
changes in pharmacokinetics; higher rates of medical and psychiatric co-morbidities; 
and an increased risk of adverse drug interactions given the greater need for com-
bining both psychotropic and nonpsychotropic agents. In the context of prescribing 
antipsychotics, these issues are amplified by their frequent use in the elderly; as well 
as the absence of a Food and Drug Administration (FDA)-approved indication and 
an FDA-mandated box warning for all drugs in this class when used in older patients 
with dementia and related psychosis.
With this background in mind, we review the diagnosis of schizophrenia in the 
elderly and its management, including the use of aripiprazole in this population.
Schizophrenia in late life
Schizophrenia affects about 1% of the general population. Its clinical presentation 
consists of positive symptoms such as delusions and hallucinations; negative symptoms 
such as anergia, anhedonia, alogia, and flat affect; cognitive disruption; and dysphoria 
with depression. The disease has a damaging effect on interpersonal relationships, 
as well as the ability to function at work and school. Most patients develop these 
symptoms in late adolescence or young adulthood and follow a relapsing course 
throughout their lives. A return to premorbid functioning is uncommon. Chronicity of 
symptoms and high recurrence rates typically require ongoing antipsychotic therapy 
to prevent relapse and improve functioning.1Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Schizophrenia  affects  0.3%  of Americans  aged 
over 65 years.2 The majority of patients with late life 
schizophrenia are those with an early-onset who are now 
elderly. A smaller proportion (approximately 25%) develop 
late-onset symptoms after the age of 40 years. Compared with 
adult patients, the elderly typically respond to lower doses of 
antipsychotic medications.3 While negative symptoms may 
persist or worsen as the patient ages, positive symptoms often 
decrease in frequency and severity. By contrast, late-onset 
schizophrenia is usually characterized by paranoid delusions 
and auditory hallucinations with less prominent negative 
symptoms.4 Schizophrenia is a costly illness for all those 
affected, and the cost of care for those aged over 65 years is 
significantly higher than for younger age groups.5 In this 
context, higher levels of medical co-morbidities and cognitive 
dysfunction are thought to contribute.
Management issues in elderly 
patients with schizophrenia
Late-life schizophrenia is also associated with high levels of 
depression.6 In turn, depression is associated with poorer qual-
ity of life, compromised daily functioning and lower income.6,7 
Suicide rates in schizophrenia, however, tend to decrease with 
age.8 Anxiety is frequently associated with depression and 
positive symptoms, further impairing quality of life.9
Cognitive dysfunction is a prominent symptom of 
schizophrenia and may be exacerbated by age-related men-
tal decline. Thus, memory, executive functioning, attention 
and new learning can be adversely affected. These cogni-
tive deficits qualitatively resemble those found in younger 
patients.10,11 Further, the impairment in social functioning 
characteristic of schizophrenia continues into older age, 
although either improvement or deterioration is possible.12 In 
this context, impaired cognitive function appears to predict 
poorer social functioning.13,14 Thus, compared with same age 
nonpsychiatric controls, older patients with schizophrenia 
have significantly more problems with finances, transporta-
tion, forming friendships, and looking after their home.14,15 
They are also less likely to live independently and more likely 
to live in supervised settings.16 Patients with schizophrenia 
have poorer coping skills and lower self-efficacy, both of 
which are associated with high levels of psychopathology.17 
Improvement in coping, however, may occur as these patients 
age. In this context, acceptance and redirecting attention 
away from unwanted thoughts or symptoms are common 
therapeutic strategies among older patients.18,19
Patients with schizophrenia usually need lifelong 
  treatment with antipsychotics. Relatively few clinical trials of 
antipsychotics agents, however, have been conducted solely 
in the elderly. Howanitz et al (1999) reported the results of 
an open-label trial comparing clozapine with chlorpromazine 
in 42 elderly subjects with schizophrenia.20 After 12 weeks, 
both agents led to improvements in the Positive and Negative 
Syndrome Scale (PANSS) and Clinical Global Improvement 
(CGI) Scale with adverse events similar between the two 
agents. A larger controlled study conducted in 117 patients 
with schizophrenia over age 60 compared olanzapine 
(5 to 20 mg daily) with haloperidol (5 to 20 mg daily) for 
six weeks.21 A greater improvement on the total PANSS 
score occurred in the olanzapine group compared with the 
haloperidol group. Jeste and Barak conducted an eight-week 
double-blind, multisite trial comparing olanzapine and risperi-
done in 175 elderly inpatients and outpatients with schizophre-
nia.22 Both treatments produced significant improvement on 
the PANSS total, positive and negative symptom scale scores. 
There was no significant difference in rates of extrapyramidal 
symptoms (EPS) between the two groups.
Since the elderly are at greater risk of developing tardive 
dyskinesia, this renders the management of their disorder 
more complicated. In addition, high levels of medical 
  co-morbidity and the resulting polypharmacy increase the 
risk for deleterious drug interactions. As previously discussed, 
impaired cognition also complicates pharmacologic treat-
ment and increases the risk of central nervous system (CNS) 
adverse events.
Role of aripiprazole
Aripiprazole
Aripiprazole, a quinolone derivative, is a second-generation 
antipsychotic (SGA) approved by the FDA for treatment of 
schizophrenia; manic and mixed episodes associated with 
bipolar disorder (either as monotherapy or as an adjunct 
to lithium or valproate); maintenance treatment of bipolar 
I disorder; and as an adjunctive treatment for inadequately 
treated major depression. Unlike any other approved antipsy-
chotic, it is a partial agonist at the D2 and D3 receptors.23 At the 
D2 receptor, it may function more as an antagonist in hyperdop-
aminergic states and as an agonist in hypodopaminergic states. 
Like other SGAs, it is also an antagonist at the 5-HT2 receptor 
with strong affinity for the 5-HT2a and 5-HT2b subtypes. In 
addition, it has partial agonist activity at the 5-HT1a receptor.
For schizophrenia, the recommended target dose range is 
10–15 mg per day with a full dose range of 5–30 mg daily. 
Aripiprazole and its active metabolite exhibit extended 
elimination half-lives (ie, approximately 75 and 95 hours, 
respectively). In this regard, there is a risk of excessive Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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accumulation, especially in the elderly, if the dose is   escalated 
rapidly. Based on pharmacokinetic studies, the product 
labeling does not recommend any specific dose adjustments 
in the elderly. For example, a study examining single dose 
administration of aripiprazole in 60 individuals did not 
demonstrate any influence of age on its pharmocokinetics.24 
Nearly 100% of both aripiprazole and its active metabolite, 
dehyro-aripiprazole, are bound to plasma protein.25 Thus, 
combining aripiprazole with other agents which are also 
highly protein bound may increase the free fraction of this 
antipsychotic to a level which may produce clinically relevant 
effects, particularly in the elderly. In this situation, a decrease 
in dose may be warranted. The drug is eliminated by hepatic 
pathways, namely the cytochome P450 (CYP) 3A4 and 2D6 
enzyme systems. Thus, dosage may need adjustment when 
administered with 3A4 inhibitors (eg, ketoconazole) and 
inducers (eg, carbamazepine) or 2D6 inhibitors (eg, parox-
etine, fluoxetine).
In adults, efficacy of this agent was demonstrated in 
several, double-blind, placebo-controlled trials for the acute 
treatment of schizophrenia.26,27 Onset of effect was noted as 
early as one–two weeks. A pooled post-hoc analysis of effi-
cacy data from five short-term studies found that aripiprazole 
improved all five PANSS factor scores (positive, negative, 
disorganized thought, depression/anxiety, and hostility) 
from baseline and was comparable to both haloperidol and 
risperidone.28 Longer-term maintenance trials lasting up to 
52 weeks also support a role for aripiprazole in the manage-
ment of chronic schizophrenia.29,30 Patients in these trials, 
however, were primarily under the age of 65.
Aripiprazole in the elderly
While trials of aripiprazole for schizophrenia primarily 
involved younger subjects, one 26-week maintenance trial 
of aripiprazole did include patients aged up to 77 years. The 
mean age of all participants was 41 years and the precise 
number of those older than 65 years was not reported. In this 
study, 310 patients with chronic schizophrenia were random-
ized to aripiprazole 15 mg daily or placebo. The primary 
outcome measure was time to relapse, which was significantly 
longer in the active treatment group compared with placebo 
(P , 0.001).29 Aripiprazole also produced significantly 
greater reductions in the PANSS total and PANSS positive 
symptom scale scores (P , 0.01). Whether aripiprazole had 
a differential effect in older subjects was not discussed.
A 52-week, open-label continuation study was conducted 
as an extension of this maintenance trial.31 Subjects from 
the original study were eligible for the extension phase if 
they were stable after completing the acute phase or met the 
original protocol criteria for relapse after completing a mini-
mum of two weeks, double-blind treatment. Participants were 
then randomized to either aripiprazole (15–30 mg daily) or 
olanzapine (10–20 mg daily). Both treatment groups achieved 
similar improvements based on change in the PANSS total 
score. Compared to aripiprazole, however, greater weight 
gain occurred in the olanzapine-treated group. Aripiprazole 
treatment also resulted in a more favorable fasting glucose 
and lipid profiles. Age was not reported to be a moderating 
factor in this analysis.
A randomized, 14-week, open-label trial examined 
two different switching strategies.32 The mean age of the 
48 participants in the two treatment groups was 54.5 (±15.0) 
and 53.0 (±17.7) years. Subjects aged over 65 years were also 
included, although the exact number was not reported. Men 
and women with schizophrenia treated with other antipsy-
chotics were either: (a) treated adjunctively with aripiprazole 
for four weeks before tapering the other antipsychotic; or 
(b) initiated on adjunctive aripiprazole with simultaneous 
tapering of the other antipsychotic. Aripiprazole was   initiated 
at 12 mg daily and titrated up to 30 mg as needed. Dosage of 
the previous antipsychotic was reduced by 25% on a biweekly 
basis. No differences were found between the groups with 
regard to the outcomes measured (ie, the Clinical Global 
Impression Scale – Schizophrenia Version, the Drug-Induced 
Extrapyramidal Symptoms Scale, and the Subjective Well-
being Under Neuroleptics, Short Version, Japanese edition). 
The authors did not report age to be a modifying factor in 
their analysis.
In addition to these studies, the use of aripiprazole in 
late-life schizophrenia is also considered in case reports. For 
example, Madhusoodan et al described the use of aripipra-
zole in elderly patients with schizophrenia or schizoaffective 
disorder.33 This retrospective review identified ten patients 
between the ages of 62 and 86 years who were previously 
treated with first or second generation antipsychotics. 
Response was based on clinical observations and the CGI-I 
Scale. Seven of the ten responded, two had a partial response 
and one did not respond. Improvement was seen in both 
negative and positive symptoms. Of the seven who improved, 
four had pre-existing symptoms of EPS which subsequently 
resolved after starting aripiprazole. Another patient with 
severe tardive dyskinesia (TD) showed improvement in the 
abnormal movements. Four of the ten patients experienced 
postural hypotension, which resolved over time; six patients 
lost weight (average 5.2 pounds); and excessive sedation and 
QTc prolongation were not reported.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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The case of a 68 year-old man with paranoid schizophrenia 
and mild intellectual dysfunction was described by Shastri 
et al.34 This patient was previously treated with risperidone 
(4 mg daily), but experienced akathisia, tremors, and tardive 
dyskinesia. Two weeks after switching to aripiprazole, his EPS 
symptoms resolved and auditory hallucinations dissipated. 
By contrast, a 72-year-old woman with schizophrenia expe-
rienced worsening of her positive symptoms after switching 
to aripiprazole.35 Previously treated with haloperidol, this 
patient was initiated on aripiprazole (7.5 mg daily) and titrated 
up to 15 mg daily. Several months later she appeared more 
interactive and communicative, but her psychosis gradually 
worsened with increased delusions and aggressive behavior. 
Trifluoperazine was introduced and her psychotic symptoms 
resolved. When the trifluoperazine was stopped several 
months later (while the aripiprazole was continued), the 
symptoms recurred. As a result, the patient was ultimately 
restabilized on trifluoperazine monotherapy.
Issues of tolerability and patient 
acceptance
SGAs, including aripiprazole, are usually associated with 
a lower risk of EPS and TD compared with FGAs. We 
emphasize, however, that the elderly are generally more 
susceptible to developing these complications when exposed 
to antipsychotics. These adverse events can be socially 
disabling and compromise treatment adherence. While not 
totally avoidable, lower risk of TD in older populations on 
SGAs may translate to relatively greater tolerability and 
medication adherence.
The adverse events seen most commonly (ie, occurring 
in $5% of patients and at least twice that for placebo) in adults 
taking aripiprazole during clinical trials included akathisia, 
sedation, restlessness, tremor, EPS, fatigue, constipation, and 
nausea. A meta-analysis of five acute schizophrenia trials 
  lasting 4 to 6 weeks, however, concluded that aripiprazole 
was generally well tolerated.36 The most common treatment-
emergent adverse effects were headache, anxiety, insomnia, 
agitation, and akathisia. The adverse event profile in longer-
term trials was similar.29,30 EPS, as measured by the Simpson 
Angus Scale (SAS), the Barnes-Akathisia Scale (BAS) and the 
Abnormal Involuntary Movement Scale (AIMS), occurred at a 
similar incidence and severity as placebo in this meta-analysis. 
Two trials,26,29 however, found a higher incidence of EPS in 
patients receiving aripiprazole compared with placebo. In 
studies with an active   comparator, EPS-related adverse events 
occurred at a similar rate to olanzapine and risperidone25 and 
less than haloperidol.36
Because of its moderate affinity for the α2 adrenergic 
receptor, aripiprazole may produce comparatively less 
orthostasis, leading to greater tolerability. We note, however, 
that elderly patients often suffer from comorbid cardiovascu-
lar and cerebrovascular disorders; usually are taking medi-
cations (eg, antihypertensives) to manage these conditions; 
and thus may be at greater risk for complications associated 
with the anti-α adrenergic effects of agents such as aripipra-
zole. Compared with other SGAs, aripiprazole is associated 
with a relatively lower risk of metabolic complications such 
as weight gain, hyperlipidemia, and diabetes mellitus.37 The 
mean weight gain in short-term trials was less than 1 kg.36 
For all doses of aripiprazole, the mean increase in weight 
(ie, 0.71 kg) was similar to haloperidol (ie, 0.56 kg).
The FDA requires a box warning regarding the use of 
antipsychotics, including aripiprazole, in elderly patients 
with dementia-related psychosis. This is due to an increased 
incidence of mortality and cerebrovascular events with these 
agents compared with placebo. Therefore, antipsychotics, 
such as aripiprazole should be avoided in this population if 
possible. When necessary, starting doses should be with the 
lowest amount possible; titration should be slow with incre-
ments also at the lowest amount; the dose should be given 
in a divided schedule; and frequent reassessment conducted 
to minimize the duration of exposure.
Adverse event-related sedation is a concern for elderly 
patients as they may be prone to experience mental status 
changes. Excessive sedation may occur with polypharmacy, 
the expectable age-related decline in cognition, and altera-
tions in drug metabolism. In this context, data from acute 
schizophrenia trials with aripiprazole in adults demonstrate 
rates of sedation (11%) similar to placebo (8%). The rate of 
somnolence was also similar to placebo and decreased over 
time. Again, these issues may be magnified in older patients 
with other forms of CNS compromise.
Antipsychotic medications are associated with prolonga-
tion of the QT interval. This is of particular concern in the 
elderly as this population is more likely to have co-morbid 
cardiovascular disease. As with sedation, data from the five 
short-term trials demonstrated a low risk of risk of QT pro-
longation in younger adults.38
Studies of aripiprazole for a variety of psychiatric disorders 
support the general safety of this agent in older individuals. 
For example, Copley et al conducted a retrospective analysis 
of 52 elderly subjects treated with aripiprazole in a university 
inpatient unit.38 The most common diagnoses included 
schizophrenia/schizoaffective disorder, bipolar disorder, major 
depressive disorder and Alzheimer’s disease. All subjects were Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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aged over 65 years: 18 (35%) were aged 65–69 years; 13 (25%) 
were aged 70–74 years; 14 (27%) were aged 75–79 years, and 
7 (13%) were aged .80 years. The mean maximum daily dose 
of aripiprazole was 13.9 (±9.4) mg. Higher doses were used 
for schizophrenia or bipolar disorder compared with major 
depression. Nine patients had documented adverse events, the 
most common being ‘agitation/activation’. EPS was reported 
in two patients; while confusion, fatigue and lightheadedness 
were reported in one patient each.
In a placebo-controlled trial of aripiprazole in 208 outpa-
tients with Alzheimer’s disease complicated by psychosis,39 
the adverse events more commonly seen in the active vs 
placebo group were: accidental injury (8%), somnolence (8%), 
bronchitis (6%), and EPS-related symptoms (5%). In another 
placebo-controlled trial of 256 elderly subjects with Alzheimer’s 
disease and psychosis, only somnolence occurred at a greater 
rate in the active treatment group (ie, 14% vs 4% in placebo).40 
The somnolence was rated mild to moderate in intensity and 
was not associated with accidental injury. In both of these 
trials, however, there was an increased rate of cerebrovascular 
events including fatalities in the aripiprazole-treated patients. 
Twenty older adults with bipolar disorder received open-label 
aripiprazole for 12 weeks.41 While no patients discontinued due 
to adverse effects, the most common events were restlessness 
(n = 3, 15.8%); weight gain over 7% of baseline level (n = 3, 
15.8%); and sedation (n = 2, 10.5%). Finally, a six-week 
augmentation study of aripiprazole was conducted in 20 older 
(ie, mean age 63 (±9.6) years) individuals with depression.42 
The most common adverse effects included dry mouth (25%), 
agitation/anxiety (20%), and drowsiness (15%).
Conclusion
As the US population continues to age, there will be an 
increasing need to prescribe antipsychotics for a variety of 
disorders, including schizophrenia. The limited evidence base 
to guide their optimal administration presents a challenge to 
clinicians. The available literature indicates that aripiprazole 
can be effective and generally well-tolerated. Important 
age-related factors, as well as the pharmacokinetics of 
aripiprazole (eg, longer elimination half-life), dictate the need 
for conservative dosing; the avoidance of polypharmacy when 
possible; careful monitoring for the development of adverse 
events and/or drug interactions; and more careful titration 
and tapering strategies.
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